Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group.

Abstract

584 Background: Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer. The purpose of this trial was to determine the activity and safety profile of bevacizumab with chemotherapy in women with LABC. METHODS Between November 2006 and August 2007, 45 women with HER-2 negative LABC initiated preoperative standard AC x 4… (More)

Topics

Cite this paper

@article{Rastogi2009BevacizumabBC, title={Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group.}, author={Priya Rastogi and M. Buyse and S. Swain and S. Jacobs and Andr{\'e} Robidoux and Michael R. Liepman and Philip A. Dy and Christopher Geyer and Norman Wolmark}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2009}, volume={27 15_suppl}, pages={584} }